Register
Login:
Share:
Email Facebook Twitter

Share Views: HUM CEO updates on Yanfolila and Dugbe Gold Projects. Watch here

Share Views Ep. 19
HUM CEO updates on Yanfolila and Dugbe Gold Projects.


Reneuron Share Price (RENE)



Share Price Information for Reneuron (RENE)


Share Price: 2.875Bid: 2.75Ask: 3.00Change: 0.00 (0.00%)No Movement on Reneuron
Spread: 0.25Spread as %: 9.09%Open: 3.25High: 3.25Low: 2.875Yesterday’s Close: 2.875

Reneuron Group Plc Ord 1P

Reneuron is listed in the FTSE AIM All-Share
Reneuron is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
2.875

Share Price SpacerBid
2.75

Share Price SpacerAsk
3.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
10,229,284

Share Price SpacerOpen
3.25

Share Price SpacerHigh
3.25

Share Price SpacerLow
2.875

Share Price SpacerClose
2.875

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 3,164.62m £90.98m 100,000

52 Week High 3.75 52 Week High Date 15-MAR-2016
52 Week Low 2.31 52 Week Low Date 18-OCT-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
91 2,128,009 8,085,626 -7.188 -0.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

02-Dec-16
14:08:58
3.00
2,500,000
Buy* 
2.75
3.00
75.00k
Trade Type:
Ordinary

02-Dec-16
14:12:18
3.00
2,500,000
Buy* 
2.75
3.00
75.00k
Trade Type:
Ordinary

02-Dec-16
16:31:38
3.00
400,000
Buy* 
2.75
3.00
12.00k
Trade Type:
Ordinary




View more Reneuron trades >>

Directors Deals for Reneuron (RENE)
Trade DateActionNotifierPriceCurrencyAmountHolding
31-Mar-16Notification of Holding
Trade Notifier Information for ReNeuron Group
Simon Christopher Cartmell held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Simon Christopher Cartmell
00787500
31-Mar-16Notification of Holding
Trade Notifier Information for ReNeuron Group
Timothy (Tim) Corn held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Timothy (Tim) Corn
00200000
31-Mar-16Notification of Holding
Trade Notifier Information for ReNeuron Group
Christopher Evans held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Christopher Evans
0024010525
View more Reneuron directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Today 22:14Fredd1eboyItalian referendum.2.875No Opinion
....looks like a no vote is likely winner. Guess this will over shadow all other tomorrows news. Typical. If it's not notice of Royal weddings or princes births it's Italian referendums....erghh
Today 20:48bogsreap2.875No Opinion
Bought my first shares at 33p, my last at 3p...is it time to reap? GLA
Today 19:56badeliNeil Woodford article2.875No Opinion
As well as the Danny Fortson 'One for the brave' article in the Sunday Times, which might well lead to further interest in RENE from PIs, there is also an excellent article in the same paper written by Neil Woodford under his own byline extolling the virtue of his patient investing model which almost cost him his job when he did not chase the dot com bubble but which instead strengthened his reputation for investing long-term in small companies which in his view have the potential to make a… Read More
Today 19:05AUNBoyRisk v Reward2.875No Opinion
The reason why I have taken a bet here is because of the potential it offers. Any research that offers disruptive technology or a new way to treat a certain disease or ailment where the technology can be commercialised can sometimes give several hundred percent return on an investment very quickly.

This may or may not happen with RENE. There is a lot of risk here. So this why RENE as an investment is "not for widows and orphans" as the ST article implied.

I however remain… Read More
Today 18:48Fredd1eboyRE: Comment RNS 17.4.152.875No Opinion
Good reminder Dibs. Well done for porting. Comforting. Best wishes. Freddie
Today 18:36Dibs61Comment RNS 17.4.152.875Buy
Quote:

"Professor Keith Muir, SINAPSE Professor of Clinical Imaging, Division of Clinical Neurosciences at the University of Glasgow, and Principal Investigator of the PISCES study, said:

"We continue to be both pleased and encouraged by the data from the PISCES study. The long term follow-up data continue to demonstrate the safety and tolerability of the CTX treatment. The evidence of functional improvement warrant further investigation and, in this regard, we are delighted to… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Reneuron (RENE) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.